Antitumor activity of LSD1 inhibitors in lung cancer.
Epigenetic machinery have become a major focus for new targeted cancer therapies. Our previous report described the discovery and biological activity of a potent, selective, orally bioavailable, irreversible inhibitor of Lysine Demethylase 1 (LSD1), GSK2879552. A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) was sensitive to LSD1 inhibition. The SCLC lines that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes suggesting this may be used as a predictive biomarker of activity. This targeted mechanism coupled with a novel predictive biomarker make LSD1 inhibition an exciting potential therapy for SCLC.
Cancer Epigenetics, GlaxoSmithKline , Collegeville, PA, USA.
Helai P
HP
Mohammad
Cancer Epigenetics, GlaxoSmithKline , Collegeville, PA, USA.
Ryan G
RG
Kruger
DNA methylation; Demethylase; LSD1; SCLC; epigenetic